When will Danaher report Q2 2026 earnings?

Danaher (DHR) is scheduled to report Q2 2026 earnings on July 21, 2026.

Has Danaher issued guidance for Q3?

No official guidance has been issued yet, but an update on the second-half outlook is expected.

How has the Masimo acquisition impacted Danaher's results?

The Masimo acquisition is expected to contribute positively to revenue and earnings, with details to be revealed in Q2 results.

Danaher Q2 2026 Earnings Preview: Bioprocessing Strength Offsets Headwinds

Q: What are the key drivers for Danaher's growth in Q2?

Key drivers include strong bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition.

Danaher (DHR) is set to report Q2 2026 results on July 21, with expectations of modest year-over-year revenue and earnings growth, supported by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition.

Danaher Corporation (DHR) is scheduled to release its second-quarter 2026 earnings on July 21, with analysts projecting modest year-over-year growth in both revenue and earnings. The anticipated growth is underpinned by robust demand in bioprocessing, enhanced filtration activity, and the initial contributions from the Masimo acquisition, despite ongoing cost pressures and higher debt levels.

Key Financial Metrics

Metric	Q2 2026 (Estimated)	YoY Change
Revenue	Modest growth	Up YoY
Net Income	Modest growth	Up YoY
EPS	TBD	—

Note: Exact figures are not yet available; estimates point to modest growth.

Highlights from the Report

Analysts are focusing on how Masimo's integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics, as well as the impact of rising input costs.

Future Guidance

No official guidance has been issued yet, but the company is expected to provide an update on its outlook for the second half of the year.

Impact on the Stock

DHR shares are trading near their 52-week highs, reflecting cautious optimism about the company's ability to sustain growth momentum.

What This Means for Investors

Investors should monitor the performance of bioprocessing and diagnostics segments, as well as the progress of Masimo integration, to assess Danaher's ability to deliver sustainable growth amid economic challenges.